Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

Judge Throws Out Teva Lawsuit Against FDA Generic Exclusivity Policy

  • Post author:Sam
  • Post published:February 28, 2019
  • Post category:Drug Industry Daily

A federal judge ruled Teva can’t challenge the FDA’s new policy on generic exclusivity because the drugmaker has not proved a danger of imminent injury. Source: Drug Industry Daily

Continue ReadingJudge Throws Out Teva Lawsuit Against FDA Generic Exclusivity Policy

FDA Warns CanaRx Over Drug Distribution ‘Scheme’

  • Post author:Sam
  • Post published:February 28, 2019
  • Post category:Drug Industry Daily

The FDA hit Canadian drug distributor CanaRx with a warning letter, citing the company for supplying unapproved versions of FDA-cleared drugs. Source: Drug Industry Daily

Continue ReadingFDA Warns CanaRx Over Drug Distribution ‘Scheme’

OGD Reports Continued Increase in First-Time Generic Approvals in 2018

  • Post author:Sam
  • Post published:February 28, 2019
  • Post category:Drug Industry Daily

The FDA’s Office of Generic Drugs released its annual report for 2018, highlighting a steady increase in first-time generic approvals and the green lighting of more than 1,000 generic drugs.…

Continue ReadingOGD Reports Continued Increase in First-Time Generic Approvals in 2018

Spanish OTC Drugmaker Nailed for Testing, Records

  • Post author:Sam
  • Post published:February 27, 2019
  • Post category:Drug Industry Daily

The FDA issued a warning letter to an OTC drug manufacturer in Catalonia, Spain, for inadequate testing of released drug products and incomplete batch records. Source: Drug Industry Daily

Continue ReadingSpanish OTC Drugmaker Nailed for Testing, Records

FTC’s Shire Appeal Denied in Fight Over Citizen Petitions

  • Post author:Sam
  • Post published:February 27, 2019
  • Post category:Drug Industry Daily

The U.S. Court of Appeals for the Third Circuit upheld a Delaware federal district court’s decision to throw out an FTC lawsuit that sought to curb alleged misuse of citizen…

Continue ReadingFTC’s Shire Appeal Denied in Fight Over Citizen Petitions

Novartis Considers Appealing $1.5 Million Whistleblower Verdict

  • Post author:Sam
  • Post published:February 27, 2019
  • Post category:Drug Industry Daily

Novartis is hinting that it will appeal a New Jersey jury’s verdict awarding $1.5 million to a former executive who alleged that the company created a bogus drug study to…

Continue ReadingNovartis Considers Appealing $1.5 Million Whistleblower Verdict

BSI Warns Devicemakers to Migrate CE Certificates Before Brexit Deadline

  • Post author:Sam
  • Post published:February 8, 2019
  • Post category:The GMP Letter

With a looming hard Brexit exit less than 60 days away, BSI is warning devicemakers that their CE certificates in the UK could become invalid if the UK and EU…

Continue ReadingBSI Warns Devicemakers to Migrate CE Certificates Before Brexit Deadline

FDA Cites Six Firms for GMP, Other Issues

  • Post author:Sam
  • Post published:February 8, 2019
  • Post category:The GMP Letter

The FDA rapped six device facilities for a variety of deficiencies identified during inspections, including problems with CAPAs and medical device reporting. Source: The GMP Letter

Continue ReadingFDA Cites Six Firms for GMP, Other Issues

China Introduces Routine Overseas Device Inspections

  • Post author:Sam
  • Post published:February 8, 2019
  • Post category:The GMP Letter

China’s National Medical Products Administration is increasing its scrutiny of foreign manufacturers and will begin routine, risk-based inspections of foreign facilities to confirm they are in compliance with Chinese regulations.…

Continue ReadingChina Introduces Routine Overseas Device Inspections

HSCC Introduces Plan for Cybersecurity ‘By Design’

  • Post author:Sam
  • Post published:February 8, 2019
  • Post category:The GMP Letter

The Healthcare and Public Health Sector Coordinating Council (HSCC) has developed a new guide for managing the security of medical devices. Source: The GMP Letter

Continue ReadingHSCC Introduces Plan for Cybersecurity ‘By Design’
  • 1
  • 2
  • 3
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company